Investment case
Ligand Pharmaceuticals Incorporated
LGND · 4 developments mapped · last assessed 2026-09-24
Market Ontology has mapped 4 macro, policy, and market developments to Ligand Pharmaceuticals Incorporated since 2026-08-27. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for LGND yet, so no modelled value is shown. The LGND valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run LGND on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Ligand Pharmaceuticals Incorporated to Acquire AvenCell Therapeutics, Inc. ($47M)
Ligand is providing financing in exchange for royalties on AvenCell's pipeline assets. This deal structure allows Ligand to gain exposure to potential future drug revenues without the full R&D and operational costs of developing the assets itself. The impact is contingent on AvenCell's clinical succ
· Moves future royalty stream projections, risk adjusted net present value (rnpv) of pipeline assets, growth rate of royalty revenue
- Open question
Ligand Pharmaceuticals Incorporated Follow-On — $6M
Capital allocation, investment in early-stage biotech, potential future royalty streams, and immediate cash outflow.
· Moves future revenue growth rate (from royalties), discount rate (risk associated with early stage investment), cash flow projections
What changed, by assumption
- 2026-09-24Ligand Pharmaceuticals Incorporated to Acquire AvenCell Therapeutics, Inc. ($47M)
- 2026-09-22Ligand Pharmaceuticals Incorporated to Acquire Sydnexis, Inc. ($23M)
- 2026-09-24Ligand Pharmaceuticals Incorporated Follow-On — $6M
- 2026-08-27MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-09-24 | Valuation multiple | Bearish | Incremental float typically compresses near-term multiple absent revenue acceleration. | 0.70 |
| 2026-09-24 | Share count | Bullish | Primary equity issuance increases diluted share count. | 0.70 |
| 2026-06-23 | Share count | Bullish | Issuance of convertible senior notes creates potential future dilution of share count upon conversion. | 0.90 |
| 2026-06-22 | Share count | Bearish | Repurchase reduces shares outstanding. | 0.70 |
| 2026-06-22 | Interest expense | Bullish | Coupon adds to interest expense until conversion. | 0.70 |
| 2026-06-22 | Dilution | Bullish | Convertible issuance creates contingent dilution at conversion price. | 0.70 |
| 2026-06-12 | Share count | Bullish | Stock component of consideration dilutes existing acquirer holders. | 0.70 |
| 2026-06-12 | Net debt | Bullish | Cash component of consideration is typically debt-funded, raising net debt. | 0.70 |
| 2026-06-12 | Revenue | Bullish | Acquisition adds target revenue to acquirer P&L on close. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-24 | Ligand Pharmaceuticals Incorporated Follow-On — $6M | mixed | 1-3m | 0.40 |
| 2026-09-24 | Ligand Pharmaceuticals Incorporated to Acquire AvenCell Therapeutics, Inc. ($47M) | Bullish | 1-5y | 0.60 |
| 2026-09-22 | Ligand Pharmaceuticals Incorporated to Acquire Sydnexis, Inc. ($23M) | Bullish | 1-5y | 0.60 |
| 2026-08-27 | MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial | watch | 1-5y | 0.10 |